IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.835
AS - Asia 8.394
EU - Europa 2.713
SA - Sud America 1.668
AF - Africa 220
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 24.838
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.634
SG - Singapore 5.597
BR - Brasile 1.393
CN - Cina 1.072
VN - Vietnam 789
FI - Finlandia 539
DE - Germania 460
IE - Irlanda 419
FR - Francia 280
IN - India 252
GB - Regno Unito 211
IT - Italia 184
HK - Hong Kong 177
NL - Olanda 146
RU - Federazione Russa 128
AR - Argentina 103
CA - Canada 84
BD - Bangladesh 82
MX - Messico 76
NG - Nigeria 72
IQ - Iraq 62
SE - Svezia 56
ZA - Sudafrica 53
PL - Polonia 52
TR - Turchia 48
EC - Ecuador 46
BE - Belgio 38
PK - Pakistan 36
CO - Colombia 34
ID - Indonesia 34
JP - Giappone 33
ES - Italia 30
SA - Arabia Saudita 29
UA - Ucraina 29
VE - Venezuela 29
CZ - Repubblica Ceca 28
IR - Iran 24
UZ - Uzbekistan 23
CL - Cile 21
MA - Marocco 21
IL - Israele 20
PY - Paraguay 18
TN - Tunisia 17
LT - Lituania 16
KE - Kenya 15
AT - Austria 14
EG - Egitto 14
JO - Giordania 13
PE - Perù 12
DO - Repubblica Dominicana 10
RO - Romania 10
AE - Emirati Arabi Uniti 9
NP - Nepal 9
PH - Filippine 9
KZ - Kazakistan 8
MY - Malesia 8
OM - Oman 8
PT - Portogallo 8
UY - Uruguay 8
CH - Svizzera 7
PS - Palestinian Territory 7
AZ - Azerbaigian 6
DZ - Algeria 6
ET - Etiopia 6
GR - Grecia 6
HN - Honduras 6
JM - Giamaica 6
KG - Kirghizistan 6
LV - Lettonia 6
TT - Trinidad e Tobago 6
AL - Albania 5
AU - Australia 5
BG - Bulgaria 5
BY - Bielorussia 5
EE - Estonia 5
LB - Libano 5
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
CI - Costa d'Avorio 4
GT - Guatemala 4
RS - Serbia 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
CR - Costa Rica 3
HR - Croazia 3
MN - Mongolia 3
SN - Senegal 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CY - Cipro 2
DK - Danimarca 2
KW - Kuwait 2
LU - Lussemburgo 2
MD - Moldavia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
Totale 24.816
Salva come PNG Salva come JPEG
Città #
Singapore 2.298
Chandler 1.802
Ashburn 1.504
San Jose 1.067
The Dalles 989
Dallas 890
Shanghai 617
Helsinki 536
Dublin 419
Boardman 398
Lawrence 390
Princeton 390
New York 282
Ho Chi Minh City 266
Paris 215
Los Angeles 204
Hanoi 199
Falkenstein 187
Wilmington 184
Beijing 161
Hong Kong 161
Amsterdam 138
São Paulo 130
Pune 115
London 95
Santa Clara 81
Benin City 68
San Mateo 65
Council Bluffs 58
Rio de Janeiro 56
Seattle 55
Ann Arbor 49
Warsaw 48
Milan 44
Phoenix 43
Moscow 42
Orem 42
Munich 41
Frankfurt am Main 40
Chennai 39
Belo Horizonte 36
Brussels 36
Brooklyn 34
Da Nang 33
Assago 30
Porto Alegre 30
Leawood 29
Curitiba 28
Brasília 27
Haiphong 27
Toronto 27
Montreal 26
Tokyo 26
Johannesburg 25
Chicago 24
Mexico City 23
Brno 22
Tashkent 22
Atlanta 21
Rome 21
Buffalo 20
San Francisco 20
Woodbridge 20
Fairfield 19
Guayaquil 19
Baghdad 18
Dhaka 18
Goiânia 18
Boston 17
Charlotte 17
Mumbai 16
Stockholm 16
Guarulhos 15
Hillsboro 15
Nairobi 15
Poplar 15
Ankara 14
Campinas 14
Manchester 14
Riyadh 14
Biên Hòa 13
Bắc Ninh 13
Amman 12
Houston 12
Oshnaviyeh 12
Quito 12
Bogotá 11
Reston 11
Fortaleza 10
Kyiv 10
Tunis 10
Berlin 9
Betim 9
Denver 9
Erbil 9
Jeddah 9
Lahore 9
Madrid 9
Manaus 9
Montes Claros 9
Totale 15.496
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 615
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 191
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 125
Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation 113
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 109
Adalimumab in active ulcerative colitis: A "real-life" observational study 106
13C-Breath Tests in the study of microsomal liver function 98
13C-breath tests in the study of mitochondrial liver function 98
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 95
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 94
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 94
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 89
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 88
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 87
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 87
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 85
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 85
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 85
DNA mismatch repair gene mutations in hereditary non polyposis colorectal cancer (HNPCC) and putative HNPCC (P-HNPCC) Italian families 85
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 83
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 82
Adalimumab in the treatment of immune-mediated diseases 82
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 80
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 78
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 77
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 75
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 74
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 74
H-pylori gastric infection and rheumatic diseases 73
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 73
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 72
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 71
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 71
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 71
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition 71
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study 70
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 70
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 70
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 70
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease 69
A novel pathogenic role for microvasculature in inflammatory bowel disease 69
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 68
Family history of peptic ulcer and a positive C-13 urea breath test are predictive of gastroduodenal ulcer disease in uninvestigated dyspeptic patients 68
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 68
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 67
Long-term scheduled therapy with infliximab in inflammatory bowel disease 67
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 67
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 67
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 67
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 66
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 66
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test 66
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 66
Role of helicobacter pylori in gastroesophageal reflux disease 66
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 66
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 66
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 65
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 65
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 65
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 65
IBD: Infliximab dose optimization in IBD-proactive or reactive? 64
Role of sucralfate in gastrointestinal diseases 64
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 64
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report 63
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 63
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 63
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 63
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study 63
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis 63
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 62
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 62
Patient Engagement in Health Management as a Mediator Between Perceived Risk and COVID-19 Related Distress in Patients With IBD: A Structural Equation Model 62
Apoptosis of epithelial cells in Helicobacter pylori associated chronic gastritis 62
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 62
C-13-methacetin breath test in patients with nonalcoholic steatohepatitis 62
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians 62
Occurence of systemic endothelial dysfunction in patients affected by ulcerative colitis and Crohn disease 62
The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars 62
Hepatic mitochondrial function assessment through C-13-methionine and C-13-sodium octanoate breath tests 61
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 61
Complex Perianal Crohn's Disease: Effectiveness of Combined Seton Placement and Anti-TNF Alpha Agents in Monotherapy or in Association With Immunosuppressants 61
Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review 61
A multistep assessment of human liver mitochondrial function through C-13-ketoisocaproate and C-13-octanoate breath tests 61
New developments in biologics therapy: what about from the medical point of view? 60
Infliximab in the treatment of glucocorticoid-dependent ulcerative colitis: a 54 week randomized methylprednisolone-controlled trial 60
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 60
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials 60
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 60
Infliximab in Steroid-Dependent Ulcerative Colitis 60
Hepatic mitochondrial beta-oxidation in patients with Nonalcoholic-Steatohepatitis (NASH) assessed by 13C-octanoate breath test 60
DISAPPEARANCE OF GASTRIC ACQUIRED MALT AND REGRESSION OF LOW-GRADE B-CLL GASTRIC LYMPHOMA BY MEAN ANTI-H-PYLORI TREATMENT 60
Can C-13 urea breath test predict resistance to therapy in Helicobacter pylori infection? 60
Mono, dual and triple moxifloxacin-based regimens for Helicobacter pylori eradication 60
Seroprevalence of hepatitis A virus and Helicobacter pylori infections in the general population of a developed European country (the San Marino study): evidence for similar pattern of spread 60
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease 60
Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD) 59
Young GI angle: Should I go abroad? 59
Levofloxacin based regimens for the eradication of Helicobacter pylori 59
Efficacy and Safety of Low-Molecular Weight Heparin for the Prevention of Venous Thromboembolism in Patients With Severe Ulcerative Colitis 59
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? 59
Totale 7.763
Salva come PNG Salva come JPEG
Categoria #
all - tutte 157.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 157.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202174 0 0 0 0 0 0 0 0 0 42 1 31
2021/2022227 6 2 11 43 3 0 7 24 19 19 50 43
2022/20235.208 842 55 423 571 430 547 7 531 960 455 333 54
2023/20243.336 219 318 781 260 112 383 184 108 26 217 337 391
2024/20254.554 95 27 49 56 40 441 222 293 905 1.252 598 576
2025/202611.297 1.818 830 895 1.068 461 701 3.741 609 657 517 0 0
Totale 24.965